Creative Planning grew its stake in shares of Sientra Inc (NASDAQ:SIEN) by 26.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 76,500 shares of the medical instruments supplier’s stock after buying an additional 15,822 shares during the period. Creative Planning owned 0.27% of Sientra worth $1,827,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in SIEN. Columbia Partners L L C Investment Management purchased a new stake in shares of Sientra in the second quarter valued at $975,000. Millennium Management LLC grew its position in shares of Sientra by 93.4% in the second quarter. Millennium Management LLC now owns 858,206 shares of the medical instruments supplier’s stock valued at $16,744,000 after purchasing an additional 414,418 shares during the period. Castleark Management LLC purchased a new stake in shares of Sientra in the second quarter valued at $2,958,000. Sei Investments Co. grew its position in shares of Sientra by 1,701.3% in the second quarter. Sei Investments Co. now owns 55,103 shares of the medical instruments supplier’s stock valued at $1,076,000 after purchasing an additional 52,044 shares during the period. Finally, Cortina Asset Management LLC purchased a new stake in shares of Sientra in the second quarter valued at $6,516,000. 89.25% of the stock is owned by institutional investors and hedge funds.
SIEN has been the subject of a number of recent analyst reports. Stephens reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Sientra in a research report on Thursday, August 9th. Stifel Nicolaus lifted their price objective on Sientra from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Canaccord Genuity lifted their price objective on Sientra from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Dougherty & Co initiated coverage on Sientra in a research report on Thursday, August 30th. They issued a “buy” rating and a $31.00 price objective for the company. Finally, BidaskClub cut Sientra from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 21st. One research analyst has rated the stock with a sell rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $22.50.
In related news, CEO Jeffrey M. Nugent sold 1,852 shares of Sientra stock in a transaction on Friday, August 31st. The stock was sold at an average price of $24.90, for a total value of $46,114.80. Following the transaction, the chief executive officer now owns 297,999 shares in the company, valued at $7,420,175.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 31.00% of the stock is currently owned by company insiders.
Shares of Sientra stock opened at $20.59 on Thursday. Sientra Inc has a twelve month low of $8.79 and a twelve month high of $26.79. The firm has a market capitalization of $546.95 million, a P/E ratio of -7.30 and a beta of -0.78. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.63 and a current ratio of 3.06.
Sientra (NASDAQ:SIEN) last issued its earnings results on Tuesday, August 7th. The medical instruments supplier reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.04). Sientra had a negative net margin of 131.16% and a negative return on equity of 151.47%. The firm had revenue of $17.55 million during the quarter, compared to analyst estimates of $15.30 million. As a group, equities research analysts predict that Sientra Inc will post -2.93 EPS for the current year.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Article: Fundamental Analysis and Individual Investors
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.